File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
  • Basic View
  • Metadata View
  • XML View
TitleTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
 
AuthorsYao, X4
Zheng, B3
Zhou, J3
Xu, DZ1
Zhao, K2
Sun, SH4
Yuan, ZH4
Wen, YM4
 
Issue Date2007
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2007, v. 25 n. 10, p. 1771-1779 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2006.11.019
 
AbstractTo study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. © 2006 Elsevier Ltd. All rights reserved.
 
ISSN0264-410X
2013 Impact Factor: 3.485
 
DOIhttp://dx.doi.org/10.1016/j.vaccine.2006.11.019
 
ISI Accession Number IDWOS:000244642700009
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYao, X
 
dc.contributor.authorZheng, B
 
dc.contributor.authorZhou, J
 
dc.contributor.authorXu, DZ
 
dc.contributor.authorZhao, K
 
dc.contributor.authorSun, SH
 
dc.contributor.authorYuan, ZH
 
dc.contributor.authorWen, YM
 
dc.date.accessioned2012-08-08T08:50:14Z
 
dc.date.available2012-08-08T08:50:14Z
 
dc.date.issued2007
 
dc.description.abstractTo study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. © 2006 Elsevier Ltd. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2007, v. 25 n. 10, p. 1771-1779 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2006.11.019
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2006.11.019
 
dc.identifier.epage1779
 
dc.identifier.isiWOS:000244642700009
 
dc.identifier.issn0264-410X
2013 Impact Factor: 3.485
 
dc.identifier.issue10
 
dc.identifier.pmid17224217
 
dc.identifier.scopuseid_2-s2.0-33846650945
 
dc.identifier.spage1771
 
dc.identifier.urihttp://hdl.handle.net/10722/157471
 
dc.identifier.volume25
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshAlanine Transaminase - Blood
 
dc.subject.meshAntigen-Antibody Complex - Immunology - Therapeutic Use
 
dc.subject.meshCytokines - Biosynthesis
 
dc.subject.meshDna, Viral - Blood
 
dc.subject.meshDendritic Cells - Immunology
 
dc.subject.meshHepatitis B Antibodies - Blood - Immunology
 
dc.subject.meshHepatitis B Surface Antigens - Immunology
 
dc.subject.meshHepatitis B E Antigens - Blood
 
dc.subject.meshHepatitis B, Chronic - Immunology - Therapy
 
dc.subject.meshHumans
 
dc.subject.meshLeukocytes, Mononuclear - Immunology
 
dc.subject.meshMiddle Aged
 
dc.titleTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yao, X</contributor.author>
<contributor.author>Zheng, B</contributor.author>
<contributor.author>Zhou, J</contributor.author>
<contributor.author>Xu, DZ</contributor.author>
<contributor.author>Zhao, K</contributor.author>
<contributor.author>Sun, SH</contributor.author>
<contributor.author>Yuan, ZH</contributor.author>
<contributor.author>Wen, YM</contributor.author>
<date.accessioned>2012-08-08T08:50:14Z</date.accessioned>
<date.available>2012-08-08T08:50:14Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Vaccine, 2007, v. 25 n. 10, p. 1771-1779</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/157471</identifier.uri>
<description.abstract>To study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 &#956;g of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 &#956;g YIC immunization showing &#8805;2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. &#169; 2006 Elsevier Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Alanine Transaminase - Blood</subject.mesh>
<subject.mesh>Antigen-Antibody Complex - Immunology - Therapeutic Use</subject.mesh>
<subject.mesh>Cytokines - Biosynthesis</subject.mesh>
<subject.mesh>Dna, Viral - Blood</subject.mesh>
<subject.mesh>Dendritic Cells - Immunology</subject.mesh>
<subject.mesh>Hepatitis B Antibodies - Blood - Immunology</subject.mesh>
<subject.mesh>Hepatitis B Surface Antigens - Immunology</subject.mesh>
<subject.mesh>Hepatitis B E Antigens - Blood</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - Immunology - Therapy</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Leukocytes, Mononuclear - Immunology</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<title>Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.vaccine.2006.11.019</identifier.doi>
<identifier.pmid>17224217</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33846650945</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33846650945&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>25</identifier.volume>
<identifier.issue>10</identifier.issue>
<identifier.spage>1771</identifier.spage>
<identifier.epage>1779</identifier.epage>
<identifier.isi>WOS:000244642700009</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Beijing Ditan Hospital
  2. Beijing Tiantan Biological Products Co. Ltd.
  3. The University of Hong Kong
  4. Ministry of Health of People's Republic of China